The information in this section of the website is intended for U.S. Healthcare Professionals
Available in 3 strengths equivalent to prednisolone 10, 15, and 30 mg.
With a pleasant taste and convenient dosage form, Orapred ODT® is an
clear therapeutic option to control severe
asthma episodes in patients with uncontrolled asthma.
Cutting-edge technology gives Orapred ODT its grape taste
Microspheres of sugar are individually layered
with prednisolone, then sealed with a dual
polymer barrier
Natural flavoring and sweetening agents help prednisolone’s unpleasant taste
Indication
Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets) is a prescription drug product indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with asthma or asthma caused by respiratory disorders.
Important Safety Information Do not break or use partial Orapred ODT tablets.
Orapred is contraindicated in patients with systemic fungal infections.
Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered, however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Orapred may cause mood swings. Adverse effects of Orapred include the following: endocrine (including development of cushingoid state, increased requirements for insulin or oral hypoglycemic agents in diabetic patients, manifestations of latent diabetes mellitus); fluid and electrolyte disturbances (including fluid retention, hypertension); gastrointestinal (including peptic ulcer with possible perforation and hemorrhage); increased appetite; and weight gain.
